Search fresh public links, source activity, and ready-to-use post angles for China Cancer Treatment.
Fresh curated links around China Cancer Treatment are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
At 25, Michael Walters had already endured unsuccessful lymphoma treatments in New Zealand. A Melbourne hospital quoted up to US$600,000 for CAR-T therapy. He paid less than half t...
For patients with advanced, metastatic cancer that has progressed despite systemic therapy – options remain critically limited. Now, Chinese scientists are pointing to an unconvent...
Lu Yong, who has a slow-growing blood and bone marrow cancer and inspired the 2018 blockbuster Dying to Survive, has begun reducing his medication and hopes to stop taking it compl...
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract...
"China has basically done to CAR-T cell therapy the same thing that it's done to other industries, which is, they've industrialized it." The post America’s Health Care System Is So...
The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from...
Cancer does not only grow; it devours. One of the most underappreciated drivers of poor outcomes in oncology is the progressive nutritional collapse that many patients experience,...
AstraZeneca has begun selling a Chinese-developed lung cancer drug in the U.S. that some American patients had been flying to China to buy.
For patients who undergo curative-intent surgery for hepatocellular carcinoma, the operation itself is only half the battle. Even when surgeons remove all visible tumor tissue, the...
There have been several promising developments lately in cancer research and treatment, including a new drug approved by the FDA this week for advanced pancreatic cancer. William B...
When faced with a rare diagnosis like peritoneal metastases, many seek treatment in Germany, known for its advanced medical care and clear communication. The country offers various...
A Chinese insurance company has paid a cancer patient’s critical illness claim after initially rejecting it on the grounds that his condition was linked to a hereditary disease, a...
A Sungkyunkwan University research team has developed an innovative cancer treatment platform in collaboration with researchers at the Korea Institute of Science and Technology (KI...
Efforts to detect multiple cancers through a single blood draw are gathering momentum after US regulators endorsed the technology for the first time, although experts say wider ado...
The rapid emergence of the Chinese biotech industry has panicked U.S. politicians, but investors and patients caution that a clampdown on pharmaceutical collaboration could hurt ev...
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
Lung cancer is still a leading cause of cancer death, but that rate is half what it was in the 1990s, partly because newly developed treatments are working.
64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive c...
While cancer continues to be a major global health challenge, it is also a rapidly changing area of medicine. Targeted therapies, immunotherapy, genomic testing, biomarker-driven t...
Lung cancer is still the top cancer killer, but new developments are shifting what the future might hold for patients.
As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space. The post More options, better odds: the changing pros...
Korean drugmaker HLB has resubmitted its application for U.S. approval of a combination therapy for advanced liver cancer, renewing its push to bring the target treatment to market...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.